Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ZS-9

- PMLiVE

Amgen leukaemia drug gets FDA priority review

Adds to breakthrough status for blinatumomab

Bristol Myers Squibb logo

BMS drops US application for ‘breakthrough’ hep C combination

Blames the 'rapidly evolving' market for asunaprevir withdrawal

Medical device firms told to address cybersecurity risks

FDA says online security should be part of a device's design and development

- PMLiVE

FDA awards $19m in rare disease grants

US regulator supports 15 orphan drug projects

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Humira gets FDA nod for paediatric Crohn’s disease

Can be used as treatment for patients as young as six

- PMLiVE

AZ: We have to be able to show mHealth can work

Still room for improvement in mobile health, Andy Jones tells ThinkDigital

- PMLiVE

Iressa blood test nears approval in Europe

Diagnostic for AZ's lung cancer drug is less invasive than current tumour biopsy method

- PMLiVE

AZ sets up joint lab with Cancer Research UK

Five-year collaboration will drive charity’s research programmes

- PMLiVE

Celgene’s Otezla gains new US psoriasis approval

FDA backs oral drug in moderate to severe plaque psoriasis

- PMLiVE

FDA approves Lilly’s GLP-1 diabetes drug Trulicity

The once-weekly treatment is set to compete with Bydureon, Tanzeum and Victoza

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links